NORTH BRUNSWICK, N.J., Sept. 21, 2022 (GLOBE NEWSWIRE) -- Lactiga Therapeutics, an early-stage biotechnology company focused on improving the quality of life of patients with primary immunodeficiency diseases, announced this week that it has oversubscribed its pre-seed financing, raising $1.6 million in new capital including over $350,000 in research grants. The lead investor in the financing was 1517 Fund, and other investors include several private firms with significant biotechnology experience.